التفاصيل البيبلوغرافية
| العنوان: |
Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases |
| المؤلفون: |
Mills, Matthew N., Walker, Chelsea, Thawani, Chetna, Naz, Afrin, Figura, Nicholas B., Kushchayev, Sergiy, Etame, Arnold, Yu, Hsiang-Hsuan Michael, Robinson, Timothy J., Liu, James, Vogelbaum, Michael A., Forsyth, Peter A., Czerniecki, Brian J., Soliman, Hatem H., Han, Hyo S., Ahmed, Kamran A. |
| المصدر: |
BMC Cancer ; volume 21, issue 1 ; ISSN 1471-2407 |
| بيانات النشر: |
Springer Science and Business Media LLC |
| سنة النشر: |
2021 |
| مصطلحات موضوعية: |
Cancer Research, Genetics, Oncology |
| الوصف: |
Background Due to recent concerns about the toxicity of trastuzumab emtansine ( T-DM1) with stereotactic radiation, we assessed our institutional outcomes treating HER2-positive breast cancer brain metastases (BCBM) with T-DM1 and stereotactic radiation. Methods This is a single institution series of 16 patients with HER2-positive breast cancer who underwent 18 stereotactic sessions to 40 BCBM from 2013 to 2019 with T-DM1 delivered within 6 months. The Kaplan-Meier method was used to calculate overall survival (OS), local control (LC), distant intracranial control (DIC), and systemic progression-free survival (sPFS) from the date of SRS. A neuro-radiologist independently reviewed follow-up imaging. Results One patient had invasive lobular carcinoma, and 15 patients had invasive ductal carcinoma. All cases were HER2-positive, while 10 were hormone receptor (HR) positive. Twenty-four lesions were treated with stereotactic radiosurgery (SRS) to a median dose of 21 Gy (14–24 Gy). Sixteen lesions were treated with fractionated stereotactic radiation (FSRT) with a median dose of 25 Gy (20-30Gy) delivered in 3 to 5 fractions. Stereotactic radiation was delivered concurrently with T-DM1 in 19 lesions (48%). Median follow up time was 13.2 months from stereotactic radiation. The 1-year LC, DIC, sPFS, and OS were 75, 50, 30, and 67%, respectively. There was 1 case of leptomeningeal progression and 1 case (3%) of symptomatic radionecrosis. Conclusions We demonstrate that stereotactic radiation and T-DM1 is well-tolerated and effective for patients with HER2-positive BCBM. An increased risk for symptomatic radiation necrosis was not noted in our series. |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1186/s12885-021-07971-w |
| DOI: |
10.1186/s12885-021-07971-w.pdf |
| DOI: |
10.1186/s12885-021-07971-w/fulltext.html |
| الإتاحة: |
https://doi.org/10.1186/s12885-021-07971-wTest |
| حقوق: |
http://creativecommons.org/licenses/by/4.0Test/ ; http://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: |
edsbas.A7AA2B40 |
| قاعدة البيانات: |
BASE |
